Article Text

PDF

Lack of clopidogrel–CYP3A4 statin interaction in patients with acute coronary syndrome
  1. D Mukherjee,
  2. E Kline-Rogers,
  3. J Fang,
  4. K Munir,
  5. K A Eagle
  1. University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to:
    Dr Debabrata Mukherjee
    Division of Cardiology, University of Michigan, Health System, 1500 E Medical Center Drive, Ann Arbor, Michigan 48103–0311, USA; dmukherjumich.edu

Abstract

Objective: To assess a clinically significant interaction between cytochrome P450 3A4 (CYP3A4) metabolised statin and clopidogrel.

Design: Prospective single centre cohort study.

Setting: Academic teaching hospital in the USA.

Patients: 1651 patients presenting with acute coronary syndromes between January 1999 and February 2003 were studied. Data on baseline demographics, co-morbidities, and in-hospital management were collected.

Main outcome measure: Association of CYP3A4 metabolised statin and clopidogrel use with in-hospital and six month mortality. The impact of the combined use of a CYP3A4 statin and clopidogrel on six month mortality and major adverse cardiac events was analysed by a risk adjusted logistic regression model.

Results: The odds ratios for six month mortality were: for CYP3A4 statin, 0.43 (95% confidence interval (CI) 0.27 to 0.71, p  =  0.0009); for CYP3A4 statin plus clopidogrel, 0.36 (95% CI 0.23 to 0.60, p < 0.001); for non-CYP3A4 statin, 0.22 (95% CI 0.08 to 0.59, p  =  0.002); and for non-CYP3A4 statin plus clopidogrel, 0.22 (95% CI 0.06 to 0.75, p  =  0.016).

Conclusions: Use of a combination of a CYP3A4 statin plus clopidogrel was associated with lower six month mortality and morbidity in patients with acute coronary syndromes. There was no significant difference in clinical benefit between a CYP3A4 statin and a non-CYP3A4 statin when used in conjunction with clopidogrel. This suggests that the proposed interaction is probably an ex vivo phenomenon and may not be clinically relevant.

  • acute coronary syndrome
  • clopidogrel
  • statin
  • drug-drug interaction
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.